MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company’s latest biolog…
Month: May 2011
3-D in Ophthalmology
Technology Spotlight
Dizzy After Cataract Surgery: An Interactive Case
Featured Article
The Myths Surrounding Latisse: Will It Turn My Blue Eyes Brown?
Featured Article
Corticosteroid Implant More Effective In Patients With Longer Duration Of DME
Two phase 3 clinical trials showed that patients who received fluocinolone acetonide implants for diabetic macular edema achieved better visual results if they had longer disease duration before treatment, according to a speaker here.
Melanoma: is hair the root of the problem?
Full Story →
ARVO: Once-Daily Glaucoma Drug Shows Promise
(MedPage Today) — An investigational, once-daily drug called tafluprost appears to lower intraocular pressure at least as well as a twice-daily glaucoma drug, researchers found.
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
Study Demonstrates Electrical Stimulation Therapy Safe And Well-Tolerated In Early Stage Retinitis Pigmentosa Patients
Okuvision GmbH, an innovator in the field of electrical stimulation therapy (EST) for early and intermediate stage retinitis pigmentosa patients, today announced the presentation of data from the company’s first sham-controlled pilot study at the Assoc…
Avastin Just as Good as Lucentis
It’s official. Avastin is just as good as Lucentis for the treatment of wet macular degeneration. The results of this National Eye Institute study were released just a week ago. The study, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)…
Study Demonstrates Benefits Of MicroPulse Photocoagulation Over Current Standard Laser Treatment Of Diabetic Macular Edema
IRIDEX Corporation today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new generation IRIDEX lasers, over the…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…
PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema
pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for th…
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented today at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects impla…
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented today at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects impla…
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects implanted i…
SAR 1118 Demonstrates Encouraging Results In Phase 2 Study Of Dry Eye Disease
SARcode Corporation presented data for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function …
Second Sight Announces Significant Results From The Argus™ II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting
Exciting results from the Argus™ II Retinal Prosthesis System (‘Argus II’) clinical trial were presented at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects implanted i…
SAR 1118 Demonstrates Encouraging Results In Phase 2 Study Of Dry Eye Disease
SARcode Corporation presented data for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function …
SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related fun…